SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: June 18, 2003
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation and Acadia Pharmaceuticals Sign Pharmaceutical
Development Agreement.
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: June 18, 2003
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Exhibit (a)
Contacts:
Rick Stewart Stefan Ohlsson
Chief Executive Officer Managing Director
Amarin Corporation plc Amarin Development A.B.
Phone: +44 (0) 20 7907 2440 Phone: +46 40 539800
Email: rick.stewart@amarincorp.com Email: stefan.ohlsson@amarindev.se
AMARIN CORPORATION AND ACADIA PHARMACEUTICALS SIGN PHARMACEUTICAL
DEVELOPMENT AGREEMENT
London, United Kingdom, 18th June 2003 - Amarin Corporation
plc (NASDAQ: AMRN) today confirmed that its Swedish subsidiary,
Amarin Development AB, has been engaged to provide pharmaceutical
formulation and manufacturing services for ACADIA Pharmaceuticals,
based in San Diego, California and Copenhagen, Denmark. The deal
centers on the continued development of ACADIA's small molecule
drug candidate ACP-103, currently in Phase I clinical studies.
ACADIA intends to utilize Amarin's services in connection with
additional clinical studies planned for ACP-103 for the treatment
of neuropsychiatric and neurological disorders.
Rick Stewart, CEO of Amarin, commented on the successful
deal, "The selection of Amarin Development by ACADIA to provide
these services underscores our strengthened position as a global
product development company. This agreement additionally makes
use of Amarin's expertise in neurology and complements the
research and development activities of Amarin Pharmaceuticals Inc.
in the US, making this a particularly attractive signing."
About ACP-103
ACP-103 is initially being pursued as a therapy for
treatment-induced dysfunctions in Parkinson's disease, an
indication that lacks adequate drug therapy. Due to its unique
profile, ACP-103 may also have broad utility in a range of other
important indications. ACP-103 is a proprietary small molecule
that acts as a selective inverse agonist at the 5-HT2A receptor.
About Amarin
Amarin Corporation plc is a specialty pharmaceutical company
focused on neurology and pain management. Amarin has multiple
pharmaceutical products on the US market along with a development
pipeline that includes two late-stage candidates: Zelapar
(selegiline HCl orally disintegrating tablets) for Parkinson's
disease and LAX-101, a proprietary compound for Huntington's
Disease. For press releases and other Company information, visit
our websites at http://www.amarincorp.com and http://www.amarinpharma.com.
About ACADIA
ACADIA Pharmaceuticals is a drug discovery and development
company that efficiently discovers novel small molecule drug
candidates using its proprietary chemical-genomics platform.
ACADIA has applied its platform to generate a broad discovery
pipeline directed at large unmet medical needs including
Parkinson's disease, chronic pain, psychosis, and glaucoma. Two of
ACADIA's drug candidates have been successfully advanced from
initial discovery to clinical development, and several additional
programs are in late-stage preclinical testing. ACADIA's
corporate headquarters as well as its biological research
facilities are located in San Diego, California and its chemistry
research facilities are located in Copenhagen, Denmark.
Statements in this press release that are not historical
facts are forward-looking statements that involve risks and
uncertainties which may cause the Company's actual results in
future periods to be materially different from any performance
suggested herein. Such risks and uncertainties include, without
limitation, risks associated with the inherent uncertainty of
pharmaceutical research, product development and
commercialization, the impact of competitive products and patents,
as well as other risks and uncertainties detailed from time to
time in periodic report, including but not limited to the filing
or approval of the NDA for Zelapar. For more information, please
refer to Amarin Corporation's Annual Report for 2002 on Form 20-F
and its Form 6-Ks as filed with the U.S. Securities and Exchange
Commission. The Company assumes no obligation to update
information on its expectations.